5-Methyl etodesnitazene human metabolism: LC-ESI±-HRMS/MS analysis (mono- and di-protonation) of human hepatocyte incubations and positive biospecimens
Authors:
- Omayema TaoussiOTOmayema Taoussi
- Jeremy CarlierJeremy Carlier
- Prince S. GameliPGPrince S. Gameli
- Laura M. HuppertzLHLaura M. Huppertz
- Giulia BambagiottiGBGiulia Bambagiotti
- Francesco TavolettaFTFrancesco Tavoletta
- Anastasio TiniATAnastasio Tini
- Diletta BerardinelliDBDiletta Berardinelli
- Francesco P. BusardòFrancesco P. Busardò
- Volker AuwärterVolker Auwärter
Open Access
- 28 April 2026
- journal article
- research article
- Published by Springer Nature in Analytical and Bioanalytical Chemistry
- Vol. 418 (12) , 3679-3694
Abstract
The rapid emergence of new synthetic opioids (NSOs), especially potent 2-benzylbenzimidazole derivatives known as nitazenes, poses challenges to public health and toxicologists. Among these substances, 5-methyl etodesnitazene has recently appeared on the illicit market. This compound was shown to be approximately twice as potent as fentanyl at the µ-opioid receptor, and overdose may lead to potentially fatal respiratory depression. Detecting the drug and its metabolites is therefore critical for clinical and forensic investigations. This study aimed to characterize the metabolic profile of 5-methyl etodesnitazene in humans. Metabolic transformations were investigated through incubations with ten-donor pooled human hepatocytes and analysis of blood and urine samples from a postmortem case positive for 5-methyl etodesnitazene. Samples were analyzed using liquid chromatography-electrospray ionization-high-resolution tandem mass spectrometry (LC-ESI-HRMS/MS) in positive- and negative-ionization modes, and software-aided data mining. In positive mode, 5-methyl etodesnitazene produced an intense signal in its di-protonated form, which generated informative spectra, facilitating structural elucidation. Biotransformations included N - and O -deethylation, consistent with structural analogs, as well as ω-carboxylation specific to the methylated benzimidazole core; phase II metabolites were not detected. We suggest N -deethyl-5-methyl etodesnitazene, N -deethyl-5-carboxy etodesnitazene, and 5-carboxy etodesnitazene in blood, and N -deethyl-5-carboxy-4′-hydroxy etodesnitazene, 5-carboxy-4′-hydroxy etodesnitazene, and N -deethyl-5-carboxy etodesnitazene in urine, as metabolite biomarkers of consumption in clinical and forensic settings. Overall, metabolite profiles were consistent across in vitro and in vivo data, with minor matrix-specific differences. Considering that nitazene metabolites are often active and their metabolism is susceptible to genetic polymorphism, further research on the pharmacokinetics and pharmacodynamics of 5-methyl etodesnitazene is warranted.Keywords
Funding Information
- Università Politecnica delle Marche
This publication has 34 references indexed in Scilit:
- Acute Intoxications and Fatalities Associated With Benzimidazole Opioid (Nitazene Analog) Use: A Systematic ReviewTherapeutic Drug Monitoring, 2022
- In silico prediction, LC-HRMS/MS analysis, and targeted/untargeted data-mining workflow for the profiling of phenylfentanyl in vitro metabolitesTalanta, 2021
- A Forward-Thinking Approach to Addressing the New Synthetic Opioid 2-Benzylbenzimidazole Nitazene Analogs by Liquid Chromatography–Tandem Quadrupole Mass Spectrometry (LC–QQQ-MS)Journal of Analytical Toxicology, 2021
- Metonitazene in the United States—Forensic toxicology assessment of a potent new synthetic opioid using liquid chromatography mass spectrometryDrug Testing and Analysis, 2021
- Synthesis, Chemical Characterization, and μ-Opioid Receptor Activity Assessment of the Emerging Group of “Nitazene” 2-Benzylbenzimidazole Synthetic OpioidsACS Chemical Neuroscience, 2021
- GLORYx: Prediction of the Metabolites Resulting from Phase 1 and Phase 2 Biotransformations of XenobioticsChemical Research in Toxicology, 2020
- Isotonitazene Quantitation and Metabolite Discovery in Authentic Forensic CaseworkJournal of Analytical Toxicology, 2020
- NERDD: a web portal providing access to in silico tools for drug discoveryBioinformatics, 2019
- European Drug Users at Risk from Illicit Fentanyls MixFrontiers in Pharmacology, 2017
- System maps for retention of small neutral compounds on a biphenylsiloxane-bonded silica stationary phase in reversed-phase liquid chromatographyJournal of Chromatography A, 2016